Innovation1 Biotech Inc. is a small molecule drug discovery company focused on the clinical development of modified Schedule 1 molecules of botanical origin, where there is the opportunity to create breakthrough advances in diseases of unmet medical need. The Company’s portfolio includes five proprietary, fully synthetic preclinical prodrugs addressing independent clinical indications: a mushroom-derived psychedelic molecule for treatment of post-traumatic stress disorder and depression, a novel cannabinoid and tree bark derived psychedelic for treatment of addiction and three additional novel cannabinoid prodrugs addressing clinical indications of refractory pediatric epilepsy, hypertrophic scarring after burn wound injury, and ocular inflammation of the cornea and anterior uvea. Innovation1 also owns a currently approved nutraceutical complex specially designed and formulated to contribute and help maintain normal energy metabolism, improve mood, and reduce fatigue for those suffering from fibromyalgia and chronic fatigue syndrome.
Company profile
Ticker
IVBT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GridIron BioNutrients, Inc., My Cloudz, Inc.
SEC CIK
Corporate docs
Subsidiaries
GridIron Ventures, Inc. ...
IVBT stock data
Latest filings (excl ownership)
NT 10-Q
Notice of late quarterly filing
17 Jan 24
10-K
2023 FY
Annual report
16 Jan 24
8-K
Entry into a Material Definitive Agreement
13 Dec 23
NT 10-K
Notice of late annual filing
29 Nov 23
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
7 Nov 23
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
16 Oct 23
10-Q
2023 Q3
Quarterly report
13 Sep 23
8-K
Entry into a Material Definitive Agreement
8 Sep 23
8-K
Departure of Directors or Certain Officers
11 Aug 23
NT 10-Q
Notice of late quarterly filing
18 Jul 23
Latest ownership filings
Financial summary
Quarter (USD) | Aug 23 | May 23 | Feb 23 | Nov 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Aug 23 | Aug 22 | Aug 21 | Aug 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 49.85 k | 49.85 k | 49.85 k | 49.85 k | 49.85 k | 49.85 k |
Cash burn (monthly) | 8.96 k | 8.89 k | (no burn) | 113.95 k | 8.96 k | 51.68 k |
Cash used (since last report) | 68.55 k | 68.00 k | n/a | 871.99 k | 68.55 k | 395.50 k |
Cash remaining | -18.70 k | -18.15 k | n/a | -822.15 k | -18.70 k | -345.66 k |
Runway (months of cash) | -2.1 | -2.0 | n/a | -7.2 | -2.1 | -6.7 |
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|